title: Current and future intratumoral targeted treatment for pancreatic cancer.
abstract: Pancreatic cancer is an insidious type of cancer with its symptoms manifested upon extensive disease. The overall 5-year survival rates between 0.4 and 4%. Surgical resection is an option for only 10% of the patients with pancreatic cancer. Local recurrence and hepatic metastases occur within 2 years after surgery. There are currently several molecular pathways investigated and novel targeted treatments are on the market. However; the nature of pancreatic cancer with its ability to spread locally in the primary site and lymph nodes indicates that further experimentation with local interventional therapies could be a future treatment proposal as palliative care or adjunct to gene therapy and chemotherapy/radiotherapy. In the current review, we will summarize the molecular pathways and present the interventional treatment options for pancreatic cancer.
authors.affiliation: Oncology Unit, Pulmonary Department, G. Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
authors.forename: Paul
authors.initials: P
authors.lastname: Zarogoulidis
authors.forename: Paschalis
authors.initials: P
authors.lastname: Pavlioglou
authors.forename: Patrick Le
authors.initials: PL
authors.lastname: Pivert
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Machairiotis
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Katsikogiannis
authors.forename: Ioanna
authors.initials: I
authors.lastname: Kougioumtzi
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Tsimogiannis
authors.forename: Stylianos
authors.initials: S
authors.lastname: Kakolyris
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Courcoutsakis
authors.forename: Theodora
authors.initials: T
authors.lastname: Tsiouda
authors.forename: Antonios
authors.initials: A
authors.lastname: Sakkas
authors.forename: Dimitra
authors.initials: D
authors.lastname: Makrantonaki
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Zarogoulidis
mesh_terms: D000091162:AMP-Activated Protein Kinase Kinases; D019942:Genes, p16; D006801:Humans; D058990:Molecular Targeted Therapy; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D018631:ras Proteins / Q000235:genetics
chemical_list: C117307:KRAS protein, human; D016328:NF-kappa B; D011518:Proto-Oncogene Proteins; D042461:Vascular Endothelial Growth Factor A; D017346:Protein Serine-Threonine Kinases; C109790:STK11 protein, human; D000091162:AMP-Activated Protein Kinase Kinases; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins